Rotigotine
Brand: Neupro (global)
Neurological
Dopamine agonist (non-ergot, transdermal patch)
Pharmacokinetics
| Half-life | 5.7 hours |
| Tmax | 15 h |
| Bioavailability | 37 % (approx) |
| Protein Binding | 92 % |
| Volume of Distribution | 84 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | yes |
| Notes | Steady plasma levels via 24-hour transdermal patch; extensive hepatic metabolism mainly via conjugation. |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
Nausea, dizziness, somnolence, hallucinations, orthostatic hypotension, skin irritation at patch site
Contraindications:
Severe hepatic impairment; hypersensitivity to rotigotine or patch components
Precautions:
Monitor for sleep attacks; avoid abrupt withdrawal to prevent NMS-like syndrome